H

    Heron Therapeuti (HRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.32
    -0.01 (-2.63%)

    Market Cap: $60.37M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -2.83%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.02+0.0%
    60d ago$-0.02+0.0%
    30d ago$-0.02+0.0%
    7d ago$-0.02+0.0%
    Current$-0.02
    Revenue Consensus
    $37M
    Range$37M - $37M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.07
    Range$-0.08 - $-0.06
    2 analysts
    Revenue Consensus
    $32M
    Range$31M - $32M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.07---
    Sep 26EST
    		-$-0.02---
    Jun 26
    Reported Aug 10
    		$-0.03$-0.02-50.00%Miss-50.0%
    Mar 26
    Reported May 11
    		$-0.04$-0.02-100.00%Miss-500.0%
    Dec 25
    Reported Feb 26
    		$-0.02$-0.03+33.33%Beat-200.0%
    Sep 25
    Reported Nov 4
    		$-0.04$-0.01-300.00%Miss-33.3%
    Jun 25
    Reported Aug 8
    		$-0.02$-0.01-100.00%Miss+66.7%
    Mar 25
    Reported May 6
    		$0.01$-0.01+200.00%Beat+150.0%
    Dec 24
    Reported Feb 27
    		$0.02$-0.03+180.00%Beat+128.6%
    Sep 24
    Reported Nov 12
    		$-0.03$-0.04+25.00%Beat+82.4%
    Jun 24
    Reported Aug 6
    		$-0.06$-0.05-20.00%Miss+82.9%
    Mar 24
    Reported May 7
    		$-0.02N/A+77.78%Beat+92.6%
    Dec 23
    Reported Mar 12
    		$-0.07N/A+53.33%Beat+58.8%
    Sep 23
    Reported Nov 14
    		$-0.17$-0.30+43.33%Beat+55.3%
    Jun 23
    Reported Aug 14
    		$-0.35$-0.23-52.17%Miss+36.4%
    Mar 23
    Reported May 11
    		$-0.27$-0.20-35.00%Miss+57.1%
    Dec 22
    Reported Mar 23
    		$-0.17$-0.28+39.29%Beat+68.5%
    Sep 22
    Reported Nov 8
    		$-0.38$-0.39+2.56%Beat+25.5%
    Jun 22
    Reported Aug 9
    		$-0.55$-0.54-1.85%Miss+11.3%
    Mar 22
    Reported May 9
    		$-0.63$-0.52-21.15%Miss-8.6%
    Dec 21
    Reported Feb 28
    		$-0.54$-0.58+6.90%Beat+20.6%
    Sep 21
    Reported Nov 3
    		$-0.51$-0.60+15.00%Beat+20.3%
    Jun 21
    Reported Aug 9
    		$-0.62$-0.57-8.77%Miss-1.6%
    Mar 21
    Reported May 10
    		$-0.58$-0.53-9.43%Miss-1.8%
    Dec 20
    Reported Feb 24
    		$-0.68$-0.65-4.62%Miss-4.6%
    Sep 20
    Reported Nov 5
    		$-0.64$-0.62-3.23%Miss-52.4%
    Jun 20
    Reported Aug 5
    		$-0.61$-0.60-1.67%Miss+3.2%
    Mar 20
    Reported May 6
    		$-0.57$-0.67+14.93%Beat+28.8%
    Dec 19
    Reported Mar 2
    		$-0.65$-0.56-16.07%Miss-3.2%
    Sep 19
    Reported Nov 12
    		$-0.42$-0.58+27.59%Beat+14.3%
    Jun 19
    Reported Aug 5
    		$-0.63$-0.62-1.61%Miss-16.7%
    Mar 19
    Reported May 9
    		$-0.80$-0.50-60.00%Miss+1.2%
    Dec 18
    Reported Feb 22
    		$-0.63$-0.46-36.96%Miss+42.2%
    Sep 18
    Reported Nov 7
    		$-0.49$-0.44-11.36%Miss+36.4%
    Jun 18
    Reported Aug 8
    		$-0.54$-0.68+20.59%Beat+32.5%
    Mar 18
    Reported May 10
    		$-0.81$-0.88+7.95%Beat+19.0%
    Dec 17
    Reported Feb 27
    		$-1.09$-0.79-37.97%Miss+10.7%
    Sep 17
    Reported Nov 6
    		$-0.77$-0.86+10.47%Beat+37.9%
    Jun 17
    Reported Aug 9
    		$-0.80$-0.91+12.09%Beat-
    Mar 17
    Reported May 10
    		$-1.00$-0.91-9.89%Miss-
    Dec 16
    Reported Feb 23
    		$-1.22$-1.23+0.81%Beat-
    Sep 16
    Reported Nov 8
    		$-1.24$-1.21-2.48%Miss-

    Key Metrics

    Valuation
    P/E Ratio-2.45EV/EBITDA35.04x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-22.50%Operating Margin-5.43%
    ROE-2409.00%ROIC-7.95%
    Financial Health
    Debt/Equity20.65xInterest CoverageN/A
    Current Ratio2.49xQuick Ratio1.51x
    Trading Statistics
    Beta1.67Avg Volume3.11M
    52-Week High$1.5752-Week Low$0.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.32
    SMA 20$0.36
    SMA 50$0.41
    SMA 200$0.90
    EMA 10$0.33
    EMA 20$0.35
    EMA 50$0.44
    EMA 200$0.84

    MACD

    Line: -0.04Signal: -0.04Hist: 0.00

    ADX

    ADX: 29.2+DI: 15.6-DI: 26.9

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down72.0
    PSAR$0.35

    Bollinger Bands

    Upper Band$0.51
    Lower Band$0.21
    %B Position8249%(Upper)
    Band Width0.36

    RSI (14-Day)

    Neutral
    34.6

    Momentum Oscillators

    Stoch %K35.8
    Stoch %D26.0
    Williams %R-67.0
    ROC (10d)-0.6%
    Momentum-0.00
    CCI (20d)-44.4
    MFI (14d)47.2

    Volatility Measures

    ATR (14d)$0.03(10.2%)
    StdDev (20d)0.07
    Hist Vol122.7%(High)

    Volume Flow

    VWAP$0.32
    OBV-84.2M
    AD Line-99.3M
    CMF (20d)-0.239

    Volume Metrics

    Avg Vol (20d)3.2M
    Vol Ratio0.7x
    VWMA (20d)$0.34

    Pivot Points

    R3$0.35
    R2$0.34
    R1$0.34
    Pivot Point$0.33
    S1$0.32
    S2$0.31
    S3$0.30

    Advanced Oscillators

    TSI-34.54
    Ultimate Osc44.9
    KST-290.42

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$37.67M$34.71M$40.59M$38.21M$37.20M$38.90M$40.78M$32.81M$36.02M$34.67M$34.23M$31.43M
    Cost of Revenue$11.57M$10.64M$11.12M$11.91M$9.86M$8.46M$10.23M$9.46M$10.52M$8.44M$9.88M$18.21M
    Gross Profit$26.09M$24.07M$29.47M$26.30M$27.34M$30.45M$30.55M$23.35M$25.51M$26.23M$24.35M$13.23M
    Operating Expenses$28.14M$28.84M$29.43M$30.39M$28.98M$27.29M$26.38M$27.81M$31.95M$31.02M$34.57M$38.16M
    R&D$2.70M$2.38M$3.75M$3.47M$2.93M$2.28M$3.18M$4.46M$4.43M$4.61M$7.80M$9.29M
    SG&A$11.28M$12.14M$13.45M$13.98M$14.47M$12.70M$12.14M$12.37M$13.90M$14.97M$14.44M$15.91M
    Operating Income$-2,044,000$-4,765,000$38,000$-4,093,000$-1,637,000$3.15M$4.17M$-4,458,000$-6,445,000$-4,798,000$-10,220,000$-24,929,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$3.44M$0$2.99M$11.34M$744,000$0$0$0$2.79M$0$0$0
    Income Before Tax$-5,489,000$-8,111,000$-2,954,000$-17,495,000$-2,381,000$2.63M$5.30M$-4,848,000$-9,235,000$-4,798,000$-10,164,000$-24,929,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,489,000$-8,111,000$-2,954,000$-17,495,000$-2,381,000$2.63M$3.66M$-4,848,000$-9,235,000$-3,160,000$-10,724,000$-25,008,000
    EBITDA$-4,961,000$-7,506,000$5.36M$-5,475,000$-1,803,000$3.12M$4.67M$-4,433,000$-9,023,000$-4,607,000$-9,908,000$-24,467,000
    EBIT$-5,489,000$-8,111,000$4.70M$-6,156,000$-2,381,000$2.63M$4.17M$-4,848,000$-9,235,000$-4,798,000$-10,220,000$-24,929,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HRTX

    News

    Tejara Capital Ltd Buys New Stake in Heron Therapeutics, Inc. $HRTX

    Tejara Capital Ltd has acquired a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) during the second quarter, purchasing over 6.51 million shares valued at approximately $2.78 million, making it their 28th largest position. Other institutional investors also modified their holdings, with institutional ownership reaching 80.01%. Heron Therapeutics shares opened at $0.31, near a one-year low, after reporting a quarterly loss of $0.03 per share and revenue below analyst estimates, leading to a consensus "Hold" rating and an average price target of $2.00 from analysts.

    MarketBeat•8/21/26•
    Somewhat-Bearish

    H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Hold Rating

    H.C. Wainwright has reiterated its Hold rating for Heron Therapeutics (HRTX.US). The article does not provide further details on the reasons for this rating or any financial analysis.

    Moomoo•8/20/26•
    Neutral

    Weekly Recap: Guidance withdrawn over CINVANTI patent and HRTX Q2 revenue $37.7M

    Heron Therapeutics Inc (HRTX) has withdrawn its 2026 sales and Adjusted EBITDA guidance due to uncertainty surrounding the CINVANTI patent and an ongoing strategic review. The company reported Q2 revenue of $37.7M, including $11.1M from ZYNRELEF and $4.2M from APONVIE, with a cash balance of $42.7M. This decision follows their financial performance snapshot for Q2 2026.

    TradingView•8/17/26•
    Bearish

    HERON THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY

    H.C. Wainwright has downgraded Heron Therapeutics Inc. from a "Buy" rating to "Neutral." This change in analyst rating indicates a revised outlook on the company's stock performance. The article, sourced from Reuters, reports on this significant financial action.

    Webull•8/13/26•
    Bearish

    H.C. Wainwright Downgrades Heron Therapeutics(HRTX.US) to Hold Rating

    H.C. Wainwright has downgraded Heron Therapeutics (HRTX.US) from a Buy to a Hold rating. This change in rating reflects a revised outlook from the firm regarding the pharmaceutical company.

    Moomoo•8/11/26•
    Bearish

    Frequently Asked Questions About HRTX

    Does HRTX pay dividends?
    Heron Therapeuti (HRTX) does not currently pay a regular dividend.
    What is HRTX's market cap?
    Heron Therapeuti (HRTX) has a market capitalization of $60.37M with a current stock price of $0.32.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In